Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New CT scan reveals how gout treatments melt crystal deposits

NCT ID NCT03965676

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study follows 50 adults with tophaceous gout who are starting or adjusting urate-lowering therapy. Researchers use a special CT scan (Dual-Energy CT) to measure how much the uric acid crystals in tophi shrink after 6 and 12 months of treatment. They also check whether bone erosions heal as the tophi get smaller. The goal is to better understand why some tophi dissolve faster than others and which locations respond best.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
urate-lowering therapy
What this could lead to
If successful, this could help doctors predict which gout patients will respond best to treatment and whether tophus shrinkage can repair bone damage.
What could go wrong
This is a small observational study (50 people) with no control group, so results may not apply broadly. It measures imaging changes, not direct patient outcomes like pain or quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2019

Expected to finish

Oct 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age greater than or equal to 18 years * Patient with a tophaceous gout * Without urate-lowering treatment or with treatment but uricemia not at target * Having given its free and informed consent to participate in this study * Affiliated with a social security system Exclusion Criteria: * Pregnant or breastfeeding woman * Participation in another intervention research or period of exclusion due to a previous research. * Impossibility to position oneself in ventral position (position for hands/wrists DECT acquisition).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Tophaceous gout are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Radiology Department Lariboisière Hospital

    Paris, Île-de-France Region, 75010, France

  • Reumatology Department Lariboisière Hospital

    Paris, Île-de-France Region, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.